Sublingual Nitroglycerin Administration with Concurrent Nitrate Patch Use

Clinical Rationale

Sublingual nitroglycerin provides rapid-onset relief for acute ischemic symptoms, while transdermal patches deliver sustained, steady-state nitrate levels for chronic prophylaxis, as recommended by the American College of Cardiology 1, 2, 3, 4
Patients presenting with ischemic pain should receive sublingual nitroglycerin regardless of background nitrate therapy, to relieve acute myocardial ischemia, according to the American Heart Association 1, 2, 3, 4

The American Heart Association recommends up to 3 doses of sublingual nitroglycerin (0.3-0.4 mg) at 3- to 5-minute intervals for patients with ongoing ischemic discomfort 5
Administer one sublingual nitroglycerin tablet (0.4 mg) dissolved under the tongue, and may repeat every 5 minutes for a total of 3 doses if symptoms persist, as suggested by the American College of Cardiology 5, 6

Do NOT administer sublingual nitroglycerin if systolic blood pressure is <90 mmHg or ≥30 mmHg below baseline, as recommended by the American Heart Association 5, 6, 7
Avoid sublingual nitroglycerin in severe bradycardia (<50 bpm) or tachycardia (>100 bpm in absence of heart failure), according to the American College of Cardiology 5, 7
Contraindicated in suspected right ventricular infarction due to preload dependence, as stated by the American Heart Association 1, 2, 3, 4, 7

Inadvertent systemic hypotension is the most serious potential complication of nitroglycerin therapy in acute myocardial infarction, according to the American College of Cardiology 1, 2, 3, 4
The combination of transdermal and sublingual nitrates increases hypotension risk, but this does not preclude use when blood pressure is adequate, as recommended by the American Heart Association 1, 2, 3, 4

Intravenous nitroglycerin is indicated for ongoing ischemic discomfort unresponsive to sublingual therapy, as suggested by the American College of Cardiology 7
IV administration allows for more precise minute-to-minute control compared to transdermal or sublingual routes, according to the American College of Cardiology 1, 2, 3, 4